Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPLP1 | P05386 | 14/20 | 1.00 |
| ▸ | RPLP0 | P05388 | 14/20 | 1.00 |
| ▸ | RPS17 | P08708 | 14/20 | 1.00 |
| ▸ | RPSA | P08865 | 14/20 | 1.00 |
| ▸ | RPS2 | P15880 | 14/20 | 1.00 |
| ▸ | RPL35A | P18077 | 14/20 | 1.00 |
| ▸ | RPL7 | P18124 | 14/20 | 1.00 |
| ▸ | RPL17 | P18621 | 14/20 | 1.00 |
| ▸ | RPS4Y1 | P22090 | 14/20 | 1.00 |
| ▸ | RPS3 | P23396 | 14/20 | 1.00 |
| ▸ | RPS12 | P25398 | 14/20 | 1.00 |
| ▸ | RPL13 | P26373 | 14/20 | 1.00 |
| ▸ | RPL10 | P27635 | 14/20 | 1.00 |
| ▸ | RPL12 | P30050 | 14/20 | 1.00 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 14/20 | 1.00 |
| ▸ | RPL22 | P35268 | 14/20 | 1.00 |
| ▸ | RPL4 | P36578 | 14/20 | 1.00 |
| ▸ | RPS19 | P39019 | 14/20 | 1.00 |
| ▸ | RPL3 | P39023 | 14/20 | 1.00 |
| ▸ | RPL13A | P40429 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176574 | 1.00 | RPLP1 (1.00) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL10271044 | 0.71 | TRPM8 (1.00) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL25194769 | 0.67 | HPGD (0.63) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL24176573 | 0.67 | NPC1 (0.55) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL4912849 | 0.67 | ALOX5 (0.52) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL25194772 | 0.67 | RPLP1 (0.49) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL31246687 | 0.67 | KCNH2 (0.55) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL16176812 | 0.66 | PCSK9 (1.00) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL31246596 | 0.66 | KCNH2 (0.59) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL8554612 | 0.66 | PDE3B (0.50) | RPLP1RPLP0RPS17RPSARPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131972-A | Microsatellite stabilized colorectal cancer combination therapy based on PCSK9 inhibitors | 广东省人民医院 | 2025-06-13 | — | — | CN | claimed |
| CN-120131972-A | Microsatellite stabilized colorectal cancer combination therapy based on PCSK9 inhibitors | 广东省人民医院 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025097061-A1 | ApoB DEGRADING COMPOUNDS AND USES THEREOF | AVILAR THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-114344466-B | Use of PCSK9 inhibitors for the preparation of products for the treatment of keratinization disorders | 陈敏 | 2024-01-02 | — | — | CN | disclosed |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | CHEN, MIN (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-113876956-B | Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation | 陈敏 | 2023-07-04 | — | — | CN | disclosed |
| CN-113876955-B | Use of PCSK9 inhibitors for the preparation of hair growth promoting products | 陈敏 | 2023-06-27 | — | — | CN | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| CN-113663075-B | Application of PCSK9 inhibitor in preparation of medicine for treating or assisting in treating tumors | 清华大学深圳国际研究生院 | 2023-03-21 | — | — | CN | disclosed |
| CN-115120730-A | Application of PCSK9 inhibitor in preparation of product for preventing and treating scars | 陈敏 | 2022-09-30 | — | — | CN | disclosed |
| CN-114432447-A | Application of PCSK9 inhibitor in preparation of medicine for treating pulmonary fibrosis | 陈敏 | 2022-05-06 | — | — | CN | disclosed |
| CN-114344466-A | Application of PCSK9 inhibitor in preparation of product for treating hyperkeratosis diseases | 陈敏 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | RPLP1 303/4885RPLP0 734/4885RPS17 620/4885 |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | PCSK9, PCSK7, PCSK6 | RPLP1 3269/4885RPLP0 4598/4885RPS17 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.